Targeting DNA Damage Response Deficiency in Thoracic Cancers

Area of Science:

• Oncology
• Genetics
• Cancer Biology

Background:

• Thoracic cancers, including non-small cell lung cancers (NSCLCs), small cell lung cancers (SCLCs), and malignant pleural mesotheliomas (MPM), are leading causes of cancer death globally.
• Genomic instability, fueled by DNA damage response (DDR) gene deficiencies, is a hallmark of cancer, driving tumor evolution.
• Homologous recombination deficiency (HRD), caused by BRCA1/BRCA2 inactivation, is a validated therapeutic target in other cancers, notably with PARP inhibitors.

Purpose of the Study:

• To review the current evidence on DNA damage response (DDR) gene deficiencies in thoracic cancers.
• To explore the therapeutic potential of targeting DDR deficiencies in thoracic malignancies.
• To discuss the challenges and opportunities for clinical benefit using DDR-targeting agents.

Main Methods:

• Literature review of studies investigating DDR gene status in thoracic cancers.
• Analysis of emerging evidence on the prevalence and functional impact of DDR deficiencies.
• Synthesis of data on the efficacy of DDR-targeting agents in preclinical and clinical settings.

Main Results:

• Genomic instability is prevalent in thoracic cancers, often linked to DDR gene alterations.
• A subset of NSCLCs, SCLCs, and MPMs exhibit DDR deficiencies, including HRD.
• Preclinical data suggest sensitivity to DDR-targeting agents, such as PARP inhibitors, in DDR-deficient thoracic cancer models.

Conclusions:

• DDR deficiencies represent a significant, yet underexplored, vulnerability in thoracic cancers.
• Targeting DDR pathways holds promise for novel therapeutic strategies in lung cancer and mesothelioma.
• Further research and clinical trials are warranted to establish the efficacy of DDR-targeted therapies in thoracic malignancies.